General Session 3: Prognostic Markers and novel Therapies

Chairs: Lewis R. Roberts, MB, ChB, PhD (USA) and Luigi Bolondi, MD (Italy)

  • O-014 Integration of Variants in Pro-Inflammatory Cytokines into Clinical Scores for the Prediction of Hepatocellular Carcinoma in Cirrhosis
    A. Tarhuni, E. Guyot, P. Rufat, A. Sutton, V. Bourcier, J. Coelho, V. Grando, V. Ganne-Carrié, M. Ziol, N. Charnaux, R. Moreau, J.-C. Trinchet0, A. Mansouri, P. Nahon

  • O-016 The Clinical Significance of Epcam Mrna-Positive Circulating Tumor Cells Detection in Hepatocellular Carcinoma by an Optimal Negative Selection and Qrt-Pcr-Based Platform
    X.-R. Yang, Y. Sun, W. Guo, J. Fan

  • O-017 Reduction of Macrophage Derived Growth Factors and Macrophage Activity Markers during Sorafenib Treatment of Hepatocellular Carcinoma
    M. F. Sprinzl, K. Ackermann, M. Schlitter, D. Hartmann, A. Weinmann, M. Schuchmann, M. Heikenwaelder, P. R. Galle, U. Protzer

  • O-018 Clinical Development of a Liver Stromal Gene Signature for Prognostic Prediction in Liver Cirrhosis and HCC
    X. Chen, K. Kojima, C. Canasto-Chibuque, M. Deshmukh, A. Villanueva, A. Sangiovanni, K. Andersson, L. King, M. Kobayashi, H. Kumada, C. Hur, R. Chung, M. Colombo, J. Llovet, Y. Hoshida